TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aclarion, Inc. ( (ACON) ) has shared an announcement.
On July 7, 2025, Aclarion, Inc. adjourned its Annual Meeting of Stockholders without conducting any business, with plans to reconvene on July 21, 2025. The adjournment aims to solicit additional votes on proposals outlined in the company’s proxy statement, with stockholders encouraged to vote by July 20, 2025. This move reflects the company’s strategic efforts to ensure comprehensive shareholder participation and decision-making.
The most recent analyst rating on (ACON) stock is a Buy with a $1.60 price target. To see the full list of analyst forecasts on Aclarion, Inc. stock, see the ACON Stock Forecast page.
More about Aclarion, Inc.
Aclarion, Inc. is a healthcare technology company that utilizes Magnetic Resonance Spectroscopy (MRS), artificial intelligence, and a proprietary biomarker to optimize clinical treatments for low back and neck pain. The company is focused on the $134.5 billion U.S. market for these conditions and is researching AI and machine learning applications to enhance the analysis of spectroscopy data.
Average Trading Volume: 29,904
Technical Sentiment Signal: Sell
Current Market Cap: $4.34M
See more data about ACON stock on TipRanks’ Stock Analysis page.